Full name

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation. (ENDURA-1)

NCT Number
NCT06959095
Geography
Non-US
Locations

TBD

Primary Endpoints

Annualized Rate of Moderate/Severe Exacerbations. Baseline up to Week 104

External Link
https://clinicaltrials.gov/study/NCT06959095
Order
1
Disease
COPD
Menu title
Depemokimab as an Extended treatmeNt Duration Biologic in Adults with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
Version
NMA 2025
Phase
3
Status
Recruiting